144 related articles for article (PubMed ID: 24132921)
21. Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases.
Klug LR; Kent JD; Heinrich MC
Pharmacol Ther; 2018 Nov; 191():123-134. PubMed ID: 29964125
[TBL] [Abstract][Full Text] [Related]
22. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
23. Low incidence of KIT gene mutations and no PDGFRA gene mutations in primary cutaneous melanoma: an immunohistochemical and molecular genetic study of Japanese cases.
Terada T
Int J Clin Oncol; 2010 Oct; 15(5):453-6. PubMed ID: 20425130
[TBL] [Abstract][Full Text] [Related]
24. Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors.
Kim TW; Ryu MH; Lee H; Sym SJ; Lee JL; Chang HM; Park YS; Lee KH; Kang WK; Shin DB; Bang YJ; Lee JS; Kang YK
Oncologist; 2009 May; 14(5):540-7. PubMed ID: 19411681
[TBL] [Abstract][Full Text] [Related]
25. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
27. Tumour heterogeneity of mucosal melanomas during treatment with imatinib.
Schoenewolf NL; Urosevic-Maiwald M; Dummer R
Br J Dermatol; 2011 Aug; 165(2):419-24. PubMed ID: 21495997
[TBL] [Abstract][Full Text] [Related]
28. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
Sihto H; Sarlomo-Rikala M; Tynninen O; Tanner M; Andersson LC; Franssila K; Nupponen NN; Joensuu H
J Clin Oncol; 2005 Jan; 23(1):49-57. PubMed ID: 15545668
[TBL] [Abstract][Full Text] [Related]
29. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
30. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
31. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
Dewaele B; Floris G; Finalet-Ferreiro J; Fletcher CD; Coindre JM; Guillou L; Hogendoorn PC; Wozniak A; Vanspauwen V; Schöffski P; Marynen P; Vandenberghe P; Sciot R; Debiec-Rychter M
Cancer Res; 2010 Sep; 70(18):7304-14. PubMed ID: 20685895
[TBL] [Abstract][Full Text] [Related]
32. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
[TBL] [Abstract][Full Text] [Related]
33. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
[TBL] [Abstract][Full Text] [Related]
34. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
35. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
Ogawa Y; Kawamura T; Furuhashi M; Tsukamoto K; Shimada S
J Dermatol Sci; 2008 Sep; 51(3):190-9. PubMed ID: 18485676
[TBL] [Abstract][Full Text] [Related]
36. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
37. Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC).
Joglekar-Javadekar M; Van Laere S; Bourne M; Moalwi M; Finetti P; Vermeulen PB; Birnbaum D; Dirix LY; Ueno N; Carter M; Rains J; Ramachandran A; Bertucci F; van Golen KL
Neoplasia; 2017 Jul; 19(7):564-573. PubMed ID: 28609680
[TBL] [Abstract][Full Text] [Related]
38. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
39. Repurposing Ponatinib as a Potent Agent against
Han Y; Gu Z; Wu J; Huang X; Zhou R; Shi C; Tao W; Wang L; Wang Y; Zhou G; Li J; Zhang Z; Sun S
Theranostics; 2019; 9(7):1952-1964. PubMed ID: 31037149
[No Abstract] [Full Text] [Related]
40. Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.
Vita M; Tisserand JC; Chauvot de Beauchêne I; Panel N; Tchertanov L; Agopian J; Mescam-Mancini L; Fouet B; Fournier B; Dubreuil P; Bertucci F; De Sepulveda P
JAMA Dermatol; 2014 Dec; 150(12):1345-9. PubMed ID: 25317746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
